Assessment of the epidemiological trends for prostate cancer using administrative data in Ontario

被引:2
作者
Saad, Fred [1 ]
Bhindi, Bimal [2 ]
Noonan, Krista [3 ]
Ong, Michael
Castellano, Kimberly [4 ]
Kourkounakis, Alexandra [4 ]
Wallis, Christopher J. D. [5 ,6 ,7 ,8 ]
机构
[1] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[2] Univ Calgary, Dept Surg, Sect Urol, Calgary, AB, Canada
[3] Univ British Columbia, BC Canc Surrey, Vancouver, BC, Canada
[4] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada
[5] Janssen Inc, Toronto, ON, Canada
[6] Vanderbilt Univ, Med Ctr, Dept Urol, Nashville, TN 37235 USA
[7] Mt Sinai Hosp, Dept Surg, Div Urol, Toronto, ON, Canada
[8] Univ Toronto, Toronto, ON, Canada
来源
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2023年 / 17卷 / 04期
关键词
RECOMMENDATIONS; SURVIVAL; CANADA; STAGE;
D O I
10.5489/cuaj.8099
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
INTRODUCTION: Studies have shown fluctuations in prostate cancer (PCa) incidence and prevalence over time and by region. Less is known about the most recent epidemiological trends by PCa disease stage. METHODS: This study was a population-based, sequential, cross-sectional analysis that used administrative health data from Ontario, Canada. After inclusion, patients were classified into non-metastatic (nm) PCa and metastatic (m) PCa. The primary study outcome was a description of temporal trends in the incidence and prevalence of PCa over the study period (2010-2019), stratified by disease state. Crude incidence and prevalence rates were estimated for each year in the study period. RESULTS: Overall, there were 131 718 men living with PCa in 2019. The incident cohort contained 86 123 patients with nmPCa (n=65 691, 76.3%), mPCa (n=8431, 9.8%), or unknown stage (n=12 001, 13.9%). The prevalence increased from 216 to 253 per 10 000 men between 2010 and 2019, respectively. Between 2011 and 2014, overall PCa incidence decreased from 20.9 to 15.4 per 10 000 men, followed by an increase to 18.8 per 10 000 in 2018. The nmPCa incidence rate was considerably higher compared with mPCa and followed a trend similar to the overall incidence. In contrast, the incidence rate for mPCa demonstrated a continuous increase from 1.5 per 10 000 in 2010 to 2.4 per 10 000 in 2018. CONCLUSIONS: The overall prevalence of PCa has risen steadily over the last decade, despite fluctuations in nmPCa incidence. The concurrent rise in mPCa and nmPCa requires further study regarding the burden of localized and systemic treatment.
引用
收藏
页码:85 / 91
页数:7
相关论文
共 20 条
  • [11] LeBlanc AG, RECENTS TRENDS PROST, DOI [10.25318/82-003-z201900400002-eng, DOI 10.25318/82-003-Z201900400002-ENG]
  • [12] UPDATE-2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging
    Mason, Ross J.
    Marzouk, Karim
    Finelli, Antonio
    Saad, Fred
    So, Alan, I
    Violette, Philippe D.
    Breau, Rodney H.
    Rendon, Ricardo A.
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 16 (04): : E184 - E196
  • [13] The future burden of cancer in Canada: Long-term cancer incidence projections 2013-2042
    Poirier, Abbey E.
    Ruan, Yibing
    Walter, Stephen D.
    Franco, Eduardo L.
    Villeneuve, Paul J.
    King, Will D.
    Volesky, Karena D.
    O'Sullivan, Dylan E.
    Friedenreich, Christine M.
    Brenner, Darren R.
    De, Prithwish
    Nuttall, Robert
    Smtih, Leah
    Demers, Paul
    Hystad, Perry
    El-Masri, Zeinab
    El-Zein, Mariam
    Narain, Tasha
    Gogna, Priyanka
    Holmes, Elizabeth
    [J]. CANCER EPIDEMIOLOGY, 2019, 59 : 199 - 207
  • [14] Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model
    Scher, Howard I.
    Solo, Kirk
    Valant, Jason
    Todd, Mary B.
    Mehra, Maneesha
    [J]. PLOS ONE, 2015, 10 (10):
  • [15] Reconsidering the Trade-offs of Prostate Cancer Screening
    Shoag, Jonathan E.
    Nyame, Yaw A.
    Gulati, Roman
    Etzioni, Ruth
    Hu, Jim C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25) : 2465 - 2468
  • [16] Siegel DA, 2020, MMWR-MORBID MORTAL W, V69, P1473, DOI 10.15585/mmwr.mm6941a1
  • [17] Cancer statistics, 2022
    Siegel, Rebecca L.
    Miller, Kimberly D.
    Fuchs, Hannah E.
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2022, 72 (01) : 7 - 33
  • [18] Statistics Canada, 2021, POP YEAR PROV TERR
  • [19] Stukel TA, 2017, ENVISIONING DATA SCI
  • [20] Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?
    Winter, Alexander
    Sirri, Eunice
    Jansen, Lina
    Wawroschek, Friedhelm
    Kieschke, Joachim
    Castro, Felipe A.
    Krilaviciute, Agne
    Holleczek, Bernd
    Emrich, Katharina
    Waldmann, Annika
    Brenner, Hermann
    [J]. BJU INTERNATIONAL, 2017, 119 (04) : 550 - 559